FYR Diagnostics

FYR's AI-powered EVO-Platform provides genomics, transcriptomics, and proteomics insights from extracellular vesicles (EVs).

The company develops diagnostic solutions based on disease insights and is a Montana CLIA laboratory focused on diagnostic needs addressed through extracellular vesicles.

Chris Howlett has more than three decades of experience in the clinical laboratory industry and has held senior and executive-level positions with clinical labs in the U.S.

Claire Seibold has more than a decade of experience in math, data science, and software engineering. At FYR, she leads a team building software and analytical pipelines and teaches biostatistics at the University of Montana.

Kirk has more than two decades of experience in oncology discovery and development projects and programs that resulted in multiple clinical candidate therapies and investigational new drugs. Kirk chairs the Glioblastoma Drug Development Summit.

Mark Adams is a venture partner at Two Bear Capital, focusing on life sciences, artificial intelligence, and cybersecurity companies. He was COO and CTO at Adaptive Biotechnologies and has held C-suite roles at other biotechnology companies.

FYR's EV-Omics (EVO) platform uses SPARCs to enrich extracellular vesicles from diseased cells and assess cellular proteins and nucleic acids from a peripheral blood sample. It uses AI-enabled multiomic insights.

FYR’s AI-powered technology reveals what DNA alone can’t – decoding RNA and protein signals in blood to power better biomarkers, smarter trials, and improved outcomes.

The notice describes how FYR Diagnostics and its affiliates collect information from or about visitors to linked websites and applications, and how they use, maintain, protect, and disclose it.